A biotechnology company focused on developing small‑molecule therapies for immune and hematologic disorders. Its lead commercial product, fostamatinib (marketed as Tavalisse), is approved for chronic immune thrombocytopenia, while additional programs target inflammatory and rare diseases through int...
No congressional trades have been disclosed for Rigel Pharmaceuticals (RIGL) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.